Request Demo

Last update 15 Feb 2026

Baclofen

Last update 15 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryBaclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis. It may also be used for hiccups and muscle spasms near the end of life. It is taken by mouth or by delivery into the spinal canal. Common side effects include sleepiness, weakness, and dizziness. Serious side effects may occur if baclofen is rapidly stopped including seizures and rhabdomyolysis. Use in pregnancy is of unclear safety while use during breastfeeding is probably safe. It is believed to work by decreasing levels of certain neurotransmitters. Baclofen was approved for medical use in the United States in 1977. It is available as a generic medication.

Drug Type

Small molecule drug

Synonyms

(+-)-Baclofen, 4-Amino-3-(4-chlorophenyl)butyric acid, Baclofen (JP17/USP/INN)

+ [25]

Target

GABAB receptor

Action

agonists

Mechanism

GABAB receptor agonists(Gamma-Aminobutyric Acid B Receptor agonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [2]

Active Indication

Multiple SclerosisSpinal Cord DiseasesSpinal Cord Injuries+ [3]

Inactive Indication

AlcoholismSpasm

Originator Organization

Novartis Pharma AG

Active Organization

Azurity Pharmaceuticals, Inc.

Alfresa Pharma Corp.Metacel Pharmaceuticals LLC

+ [5]

Inactive Organization

UCB, Inc.Strides Pharma International AG

Impax Laboratories LLC

+ [3]

License Organization

Hemony Pharmaceutical Co., Ltd.

Novartis AG

Drug Highest PhaseApproved

First Approval Date

United States (22 Nov 1977),

Spasm

RegulationOrphan Drug (United States), Orphan Drug (Japan), Priority Review (China)

Structure/Sequence

Molecular FormulaC10H12ClNO2

InChIKeyKPYSYYIEGFHWSV-UHFFFAOYSA-N

CAS Registry1134-47-0

175

Clinical Trials associated with Baclofen

NCT05935553

/ RecruitingPhase 2/3IIT

Baclofen for Improving Benzodiazepine Titration in Benzodiazepine Dependence

Benzodiazepines and related molecules are among the most prescribed psychotropic treatments in France and Europe. 13.4% of the French population had at least one reimbursement of benzodiazepines in 2015, which places France second in Europe.
However, the chronic use of benzodiazepines is a source of numerous complications, particularly addictive. To date, there is no authorized pharmacological treatment for benzodiazepine withdrawal.
Baclofen is a gamma-aminobutyric acid (GABA)-B agonist, a pharmacological receptor that regulates GABA-A, the target of benzodiazepines. The pharmacological mechanisms of baclofen are therefore related to those of benzodiazepines. Empirical use outside of the MA has shown that baclofen can facilitate the reduction of benzodiazepines in cases of severe addiction, but this pharmaceutical interest remains to be demonstrated in a comparative study.
The main objective of the project is to evaluate the efficacy of baclofen, compared to placebo, in reducing benzodiazepine doses in patients with benzodiazepine use disorder (BUD).

Start Date15 Jan 2026

Sponsor / Collaborator

Hospices Civils de Lyon

CTIS2024-518822-33-01

/ Not yet recruitingPhase 4

Intrathecal baclofen pump versus selective dorsal rhizotomy for non-ambulatory children with cerebral palsy

Start Date01 Jan 2026

Sponsor / Collaborator

UZ Leuven

NCT07378046

/ RecruitingNot ApplicableIIT

The Analgesic Efficacy and Safety of Oral Medications (Baclofen) in Patients With Herpes Zoster

Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of muscle relaxant, which can relieve skeletal muscle spasms and associated pain in acute musculoskeletal conditions. Therefore, investigators hypothesize that baclofen may effectively reduce the severity of HZ pain without significantly increasing adverse events.

Start Date15 Dec 2025

Sponsor / Collaborator

Beijing Tiantan Hospital

100 Clinical Results associated with Baclofen

100 Translational Medicine associated with Baclofen

100 Patents (Medical) associated with Baclofen

7,784

Literatures (Medical) associated with Baclofen

01 Apr 2026·Annals of Physical and Rehabilitation Medicine

Specific procedure combinations in a rehabilitation setting define severity clusters of older adults with multiple sclerosis: a cohort study

Article

Author: Léotard, Antoine ; Bensmail, Djamel ; Joussain, Charles ; Castro, John ; Levy, Jonathan ; Espagnacq, Maude ; Salga, Marjorie ; Leilaz, Arnaud ; Heinzlef, Olivier

INTRODUCTION:

People with multiple sclerosis (PwMS) are ageing and exposed to multiple impairments. We described the use of health care procedures in a physical and rehabilitation medicine setting for PwMS ≥70 years and identified specific participant clusters.

METHODS:

In this observational cohort study using a local data hub (2012 to March 2024), PwMS were identified with ICD-10 codes (G35). An age filter (≥70) was applied. Medical procedures were systematically coded according to a specific French classification over time, including dates of occurrence, and then extracted and grouped by impairment domains: upper motor neuron syndrome and orthopedic deformities (UMN-OD), respiratory and sleep disorders (RSD), and neurogenic lower urinary tract dysfunction (NLUTD). Clinical data were retrospectively collected from medical files. We conducted descriptive analyses and multiple-component and clustering analyses to identify and characterize the participants' profiles.

RESULTS:

Among 206 participants aged 75.7 (4.3) years, 62% (128) were women, 19% (39) had died, and MS had evolved for 43.3 (12.4) years. The Expanded Disability Status Scale (EDSS) was 7.5 (6.5-8.5), and the Charlson Comorbidity Index (CCI) was 6 (5-7). A total of 2794 procedures were performed for 187 participants, mainly in NLUTD (1424 for 170), which was associated with RSD (P = 0.001), but not UMN-OD (P = 0.262). Three groups were identified (Group 1 = isolated NLUTD, Group 2 = RSD and intrathecal baclofen procedures, and Group 3 = no in-hospital management). People in Group 2 had more severe comorbidities (P < 0.001) than those in the other two groups (P = 0.016).

CONCLUSIONS:

In PwMS ≥70 years, the hospital management of MS-related impairments was directly associated with disease severity and overall comorbidities. Participants who were followed only for NLUTD exhibited severity and comorbidity profiles similar to those of participants who did not require hospital procedures.

DATA REGISTRATION:

Our institutional health data warehouse and all derived extracted databases within the scope of the health team perimeter are approved by the French Data Protection Authority under the No. 1980120.

01 Mar 2026·JOURNAL OF THE NEUROLOGICAL SCIENCES

Opisthotonus: Revisiting a classic movement disorder

Review

Author: Baizabal-Carvallo, José Fidel ; Jankovic, Joseph

Opisthotonus is characterized by backward arching of the trunk, associated with retrocollis, caused by involuntary contractions of extensor paraspinal muscles. Classical etiologies include tetanus, strychnine intoxication, dystonia (particularly tardive dystonia and neurodegeneration with brain iron accumulation), seizures, and functional movement disorders (MDs). Inborn errors of metabolism, epileptic encephalopathies and other gene mutations should be considered in newborns and infants presenting with opisthotonus. We surveyed 1216 consecutive patients presenting for evaluation in a tertiary care center for MDs and identified 17 (1.4%) with opisthotonus. Functional opisthotonus represented the most common cause, present in 9 (53%) patients. Other etiologies included tardive dystonia (n = 2), dystonia secondary to cavernous hemangioma in the basal ganglia (n = 1), dystonia due to hypoxic encephalopathy (n = 1), and 4 with idiopathic dystonia. Identifying the underlying etiology of opisthotonus is important to guide therapeutic strategies. Benzodiazepines, baclofen, anticholinergics, and botulinum toxin are common pharmacological options, whereas deep brain stimulation and surgical correction of the underlying cause should be considered in selected cases.

01 Mar 2026·NEUROBIOLOGY OF DISEASE

The role of auxiliary GABAB receptor subunit KCTD16 in pain modulation

Article

Author: Heles, Mario ; Turecek, Rostislav ; Bhattacharyya, Anirban ; Palecek, Jiri ; Vasconcelos, Daniel ; Melichar, Adolf ; Adamek, Pavel

Chronic pain affects nearly 10% of the global population and remains a major clinical challenge due to the limited efficacy and adverse effects of current therapies. In this study, we identify the potassium channel tetramerization domain protein KCTD16 as a key modulator of GABA_B receptor mediated inhibition of nociceptive transmission. Immunohistochemical analysis revealed prominent KCTD16 expression in dorsal horn and dorsal root ganglion (DRG) neurons, consistent with a role in spinal nociceptive processing. KCTD16 knockout (KO) mice exhibited increased mechanical thresholds relative to wild-type (WT) littermates, while thermal sensitivity remained unchanged; this phenotype persisted following carrageenan-induced inflammation. The GABA_B receptor agonist Baclofen produced strong analgesic effects in WT mice under both basal and inflammatory conditions, whereas its anti-allodynic efficacy was significantly reduced in KO animals. Whole-cell patch-clamp recordings from dorsal horn neurons showed comparable baseline miniature excitatory and lower inhibitory postsynaptic currents (mEPSCs and mIPSCs) for KCTD16^-/-. However, following inflammation, Baclofen-induced suppression of excitatory transmission was potentiated in WT but markedly attenuated in KO neurons. Light-evoked synaptic inhibitory currents and calcium imaging of cultured DRG neurons further demonstrated enhanced Baclofen sensitivity in WT cells. These findings indicate that KCTD16 plays a critical role in presynaptic modulation of inhibitory control in the spinal dorsal horn, affecting the balance between the excitation and inhibition in nociceptive circuits. Collectively, these results demonstrate that KCTD16 modulates GABA_B receptor-dependent inhibitory control of nociceptive signaling and highlight the GABA_B receptor-KCTD16 complex as a promising new molecular target for effective pain treatments.

News (Medical) associated with Baclofen

15 Dec 2025

·www.businesswire.com

Trends Shaping the $5 Billion Spasticity Treatment Market, 2026-2034: Focus on Multimodal Care and Treatment Innovations - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Spasticity Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis" has been added to ResearchAndMarkets.com's offering. The global Spasticity Treatment Market, valued at USD 5.02 billion in 2025, is set to expand at a CAGR of 5.5%, reaching USD 8.13 billion by 2034. This growth is driven by innovations in pharmacologic therapies, interventional procedures, and multimodal rehabilitative modalities designed to manage spasticity associated with various neurological conditions. Key areas of focus include post-stroke rehabilitation, cerebral palsy, multiple sclerosis, spinal cord injuries, and traumatic brain injuries. The market is marked by a shift towards personalized treatment approaches, whereby oral antispasmodics, botulinum toxin injections, and intrathecal baclofen pumps are tailored to individual patient needs. Image-guided chemodenervation, device miniaturization, and remote monitoring are emerging trends enhancing treatment efficacy and patient outcomes. Key drivers of market growth include increased stroke survival rates, aging populations, improved diagnosis of pediatric neuromotor disorders, and payer recognition of treatments that reduce falls, contractures, and caregiver burden. Providers are distinguishing themselves through multidisciplinary clinics, reduced wait times, and protocolized treatments that emphasize measurable improvements in patient mobility and quality of life. In terms of regional insights, North America leads with comprehensive neurorehabilitation networks, Europe sees guideline-driven practices with strong focal injection adoption, and the Asia-Pacific region is expanding access due to rising MS awareness and growing pediatric neurology services. Meanwhile, Middle East & Africa and South & Central America are witnessing investments in rehabilitation infrastructure and caregiver education programs. The Spasticity Treatment Market segmented by type includes drug therapy, physical therapy, and surgical treatment, while end-users comprise hospitals, ambulatory surgical centers, specialty clinics, and diagnostic centers. Prominent market players include Amcor plc, Silgan Holdings, Inc., and Ardagh Group. The competitive space is characterized by strategic initiatives such as mergers, technology collaborations, and regional expansions that aim to advance product innovation and market reach. The report addresses market size forecasts, growth potential across segments, supply chain adaptations, and the impact of geopolitical shocks like the Russia-Ukraine conflict on trade and costs. Key Attributes Key Topics Covered 1. Table of Contents 2. Global Spasticity Treatment Market Summary, 2025 2.1 Spasticity Treatment Industry Overview 2.2 Spasticity Treatment Market Scope 2.3 Research Methodology 3. Spasticity Treatment Market Insights, 2024-2034 3.1 Spasticity Treatment Market Drivers 3.2 Spasticity Treatment Market Restraints 3.3 Spasticity Treatment Market Opportunities 3.4 Spasticity Treatment Market Challenges 3.5 Tariff Impact on Global Spasticity Treatment Supply Chain Patterns 4. Spasticity Treatment Market Analytics 4.1 Spasticity Treatment Market Size and Share 4.2 Five Forces Analysis for Global Spasticity Treatment Market 5. Global Spasticity Treatment Market Statistics 6. Asia Pacific Spasticity Treatment Industry Statistics 6.1 Asia Pacific Spasticity Treatment Market Insights 6.2 Asia Pacific Spasticity Treatment Market Revenue Forecast 6.3 Asia Pacific Spasticity Treatment Market Revenue Forecast by Country 7. Europe Spasticity Treatment Market Data 7.1 Europe Spasticity Treatment Market Key Findings 7.2 Europe Spasticity Treatment Market Size and Percentage Breakdown 7.3 Europe Spasticity Treatment Market Size and Percentage Breakdown by Country 8. North America Spasticity Treatment Market Size, Growth Trends, and Future Prospects 8.1 North America Snapshot 8.2 North America Spasticity Treatment Market Analysis and Outlook 8.3 North America Spasticity Treatment Market Analysis and Outlook by Country 9. South and Central America Spasticity Treatment Market Drivers, Challenges, and Future Prospects 9.1 Latin America Spasticity Treatment Market Data 9.2 Latin America Spasticity Treatment Market Future 9.3 Latin America Spasticity Treatment Market Future by Country 10. Middle East Africa Spasticity Treatment Market Outlook and Growth Prospects 10.1 Middle East Africa Overview 10.2 Middle East Africa Spasticity Treatment Market Statistics 10.3 Middle East Africa Spasticity Treatment Market Statistics by Country 11. Spasticity Treatment Market Structure and Competitive Landscape 11.1 Key Companies in Spasticity Treatment Industry 11.2 Spasticity Treatment Business Overview 11.3 Spasticity Treatment Product Portfolio Analysis 11.4 Financial Analysis 11.5 SWOT Analysis Key Companies Featured For more information about this report visit https://www.researchandmarkets.com/r/aj5h9l About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

12 May 2025

·www.globenewswire.com

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be started. “Our partner Indivior has made great progress with their GABAB PAM substance use disorders program, successfully completing the last preclinical safety and toxicity studies with the compound they selected from our research collaboration. This significant achievement demonstrates the quality of the compounds discovered by the Addex team,” said Tim Dyer, CEO of Addex. “Our own GABAB PAM cough program is also advancing through preclinical studies and is scheduled to start IND enabling studies later this year.” As previously announced, Indivior has selected a GABAB PAM for future development in substance use disorders as part of a research collaboration between the two companies. Under the terms of the agreement, Addex is eligible for payments of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. As part of the same agreement, Addex has selected a compound for it own independent GABAB PAM program and is advancing this program for the treatment of chronic cough. About GABAB Activation with PAM:Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, overactive bladder, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. Novel, potent, selective and orally available PAMs that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have fewer adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the receptor, hence respecting the physiological cycle of activation, which may explain why PAMs lead to less tolerance than direct agonists. About Addex Therapeutics Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

License out/in

18 Mar 2025

·www.pharmaindustrial-india.com

Marksans Pharma's Subsidiary Relonchem Secures Marketing Authorisation from UK MHRA for Baclofen 10 mg Tablets

Marksans Pharma Ltd. has announced that its wholly-owned subsidiary, Relonchem Ltd., has received Marketing Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets. Baclofen is commonly prescribed for muscle spasms associated with multiple sclerosis, spinal cord injuries, and neurological disorders. This approval enhances Marksans Pharma’s presence in the UK pharmaceutical market, reinforcing its commitment to delivering high-quality, affordable medicines worldwide. Marksans Pharma, headquartered in Mumbai, is engaged in research, manufacturing and marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, the USA and the UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.

Drug Approval

100 Deals associated with Baclofen

External Link

KEGG	Wiki	ATC	Drug Bank
D00241	Baclofen	M03BX01	DB00181

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spinal Cord Diseases	United States	Metacel Pharmaceuticals LLC	18 Sep 2019
Spinal Cord Injuries	United States	Metacel Pharmaceuticals LLC	18 Sep 2019
Hereditary Spastic Paralysis, Infantile Onset Ascending	Japan	Daiichi Sankyo Co., Ltd.	11 Apr 2005
Multiple Sclerosis	United States	UCB, Inc.	30 Oct 2003
Muscle Spasticity	United States	Amneal Pharmaceuticals LLC	17 Jun 1992
Spastic paralysis	Japan	Sun Pharma Japan Ltd.	27 Aug 1979
Spastic paralysis	Japan	Alfresa Pharma Corp.	27 Aug 1979
Spasm	United States	Novartis Pharmaceuticals Corp.	22 Nov 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alcoholism	Phase 3	France	Ethypharm SAS	01 Dec 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04251819 (CTgov)	Phase 2/3	Analgesia \| Acute Pain	19	Placebos (Placebo)	exkaxjtrjm(hnbnxkodte) = ygqswcgtwr icspddexmp (xapvkveshf, 2.13) View more	-	07 Jan 2026
				Baclofen 5 mg (Baclofen 5mg)	exkaxjtrjm(hnbnxkodte) = xeyzolkbot icspddexmp (xapvkveshf, 3.04) View more
EULAR2025	Not Applicable	Pain	181,677	Baclofen	addjfvjajf(ggkdrznxkj) = pujyqtomok eiszaqwzva (rhfxlwjxgk ) View more	Positive	11 Jun 2025
				Cyclobenzaprine	addjfvjajf(ggkdrznxkj) = bqrzlshuqj eiszaqwzva (rhfxlwjxgk ) View more
NCT05161351 (FORWARDS-1, CTgov)	Phase 4	Heroin Dependence \| opioid dependence methadone	16	Vitamin D3	lfrqbmwtjm = mskefaszof wglsgncxcl (rdlgjqhqop, gkskkvuaby - ukbvooaenv) View more	-	18 Nov 2024
ACR2024	Not Applicable	Musculoskeletal Diseases	638,083	Cyclobenzaprine	dgljrbrbcl(jpfqwhguve) = dsmovqohgt wcwdbwnatu (ahercxnmeg ) View more	Similar	10 Nov 2024
				Baclofen	dgljrbrbcl(jpfqwhguve) = knjlpjjdjt wcwdbwnatu (ahercxnmeg ) View more
NCT03720717 (CTgov)	Phase 4	Pain	34	Baclofen 10mg (Opioid Tolerant - Baclofen)	hcexybmpgs(lfbkrfuwil) = zgpfbhjnyx uuysbozhvw (lpcmsioqvs, 33.6) View more	-	05 Sep 2024
				Placebo (Opioid Tolerant - Placebo)	hcexybmpgs(lfbkrfuwil) = ioyphorczz uuysbozhvw (lpcmsioqvs, 17.1) View more
NCT02998151 (CTgov)	Early Phase 1	Fragile X Syndrome	29	placebo (Placebo)	preuvpwvfr(qfmaqwvdbi) = fjdvfrctii hucnlwbrtj (iemateafsc, .0265) View more	-	24 Nov 2021
				Acamprosate (Acamprosate)	preuvpwvfr(qfmaqwvdbi) = knfsxpsrgs hucnlwbrtj (iemateafsc, 0.0252) View more
NCT02723383 (Pubmed \| JAMA)	Phase 3	Alcoholism	314	Baclofen	swzmtrbnab(ozbfdryrjl) = cfsaautalu glswrccykc (yudtlhnjsd ) View more	Positive	23 Feb 2021
				Placebo	swzmtrbnab(ozbfdryrjl) = tvsfeftfnt glswrccykc (yudtlhnjsd ) View more
NCT03068897 (CTgov)	Phase 4	Low Back Pain	320	Educational intervention+Ibuprofen 600 mg+Metaxalone (Metaxalone)	bhfclgwucn(ttzsztemqj) = mstsgymurx oxwemucbtp (zsebeirsyu, aubzaomwkg - dtkmvnsbxu) View more	-	12 Aug 2020
				Educational intervention+Ibuprofen 600 mg+Tizanidine (Tizanidine)	bhfclgwucn(ttzsztemqj) = zilrbpwcmu oxwemucbtp (zsebeirsyu, rhasuvvflu - wwehjkazqu) View more
ASN2019	Not Applicable	-	-	Baclofen ≥ 20 mg/day	ieoszpoyka(webpeszabm) = auplgxuisg gzdcnguhls (lgkzpujkhj )	Negative	05 Nov 2019
				Baclofen <20 mg/day	ieoszpoyka(webpeszabm) = pqqkysxkld gzdcnguhls (lgkzpujkhj )
NCT01980706 (CTgov)	Phase 2	Alcoholism	120	Placebo (Placebo)	ruiscfrytg(scuuhutecw) = vfzbzwroag botbphhnod (xhjnzbdsyq, 4) View more	-	08 Jan 2019
				Baclofen (30 Mg Baclofen)	ruiscfrytg(scuuhutecw) = swmlzgwbvo botbphhnod (xhjnzbdsyq, 4) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis